Dyne Therapeutics, Inc. (NASDAQ:DYN) Position Boosted by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. increased its stake in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 7.9% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 648,652 shares of the company's stock after buying an additional 47,590 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.65% of Dyne Therapeutics worth $23,300,000 as of its most recent filing with the SEC.

Other hedge funds have also modified their holdings of the company. First Light Asset Management LLC grew its stake in Dyne Therapeutics by 261.0% during the 2nd quarter. First Light Asset Management LLC now owns 382,433 shares of the company's stock valued at $13,496,000 after purchasing an additional 276,485 shares in the last quarter. Marshall Wace LLP grew its position in shares of Dyne Therapeutics by 409.4% during the second quarter. Marshall Wace LLP now owns 273,567 shares of the company's stock worth $9,654,000 after buying an additional 219,862 shares in the last quarter. Renaissance Technologies LLC bought a new stake in shares of Dyne Therapeutics in the second quarter worth $4,447,000. Avoro Capital Advisors LLC bought a new position in Dyne Therapeutics during the 2nd quarter valued at $4,085,000. Finally, Federated Hermes Inc. boosted its stake in Dyne Therapeutics by 10.4% during the 2nd quarter. Federated Hermes Inc. now owns 1,215,112 shares of the company's stock valued at $42,881,000 after acquiring an additional 114,888 shares during the last quarter. 96.68% of the stock is currently owned by hedge funds and other institutional investors.

Dyne Therapeutics Price Performance

Shares of DYN traded up $1.76 during trading hours on Friday, reaching $29.50. 1,099,814 shares of the company's stock traded hands, compared to its average volume of 1,460,237. Dyne Therapeutics, Inc. has a twelve month low of $10.33 and a twelve month high of $47.45. The firm has a market capitalization of $3.00 billion, a price-to-earnings ratio of -8.25 and a beta of 1.09. The business's fifty day simple moving average is $31.21 and its two-hundred day simple moving average is $35.39.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last announced its earnings results on Tuesday, November 12th. The company reported ($0.96) EPS for the quarter, missing the consensus estimate of ($0.71) by ($0.25). On average, equities research analysts expect that Dyne Therapeutics, Inc. will post -3.45 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the stock. HC Wainwright reaffirmed a "buy" rating and set a $55.00 price target on shares of Dyne Therapeutics in a research report on Wednesday, November 13th. Chardan Capital reaffirmed a "buy" rating and set a $50.00 target price on shares of Dyne Therapeutics in a report on Wednesday, November 13th. Piper Sandler reiterated an "overweight" rating and issued a $53.00 price target on shares of Dyne Therapeutics in a report on Monday, September 23rd. Oppenheimer restated an "outperform" rating and set a $55.00 price objective on shares of Dyne Therapeutics in a research note on Tuesday, September 3rd. Finally, Morgan Stanley boosted their target price on shares of Dyne Therapeutics from $48.00 to $52.00 and gave the company an "overweight" rating in a research note on Wednesday, August 14th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $50.82.

Insider Activity at Dyne Therapeutics

In other news, Director Carlo Incerti sold 16,500 shares of the business's stock in a transaction on Monday, November 18th. The stock was sold at an average price of $28.73, for a total transaction of $474,045.00. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, COO Susanna Gatti High sold 8,976 shares of the company's stock in a transaction on Wednesday, September 18th. The shares were sold at an average price of $34.41, for a total value of $308,864.16. Following the sale, the chief operating officer now directly owns 131,636 shares of the company's stock, valued at approximately $4,529,594.76. This represents a 6.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 176,257 shares of company stock valued at $6,193,718 over the last 90 days. 20.77% of the stock is currently owned by corporate insiders.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.